Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Mediahype van invloed op keuzes bij adjuvante behandeling melanoom?
apr 2019 | Dermato-oncologie, Immuuntherapie